Wednesday, November 7, 2012

NOVARTIS R&D INVESTOR DAY - HIGHLIGHTS

  1. Afinitor now expected to contribute USD 2 billion sales in advanced breast cancer alone by 2017
  2. Filing of RLX030 planned to commence in early 2013 in US and EU
  3.  LAMA/LABAs, including QVA149 have potential to become new standard of care for COPD
  4. In 2013 the Novartis plans to initiate Tasigna clinical trials to explore the goal of achieving sustained treatment-free remission in patients living with CML. If positive, this could lead to a major paradigm shift in CML treatment
  5. Novartis has initiated a broad scale clinical development program named PRISM for its leading PI3K inhibitor BKM120 across multiple indications, both as a single agent and in combination with other therapeutic agents in various breast cancer settings, as well as other indications. 
  6.  Regulatory filing for  AIN457 in psoriasis is expected to start in late 2013

Enter your email address:


Delivered by FeedBurner